May 20, 2024
U.S. Acellular Dermal Matrices

The Global Acellular Dermal Matrices Market is Driven by Growing Plastic and Reconstructive Surgeries

Acellular dermal matrices, also known as acellular human dermal matrices, are three-dimensional scaffolds that mimic human dermal tissue and are derived from human or porcine skin that has been decellularized. These scaffolds are used in plastic and reconstructive surgical procedures to repair or replace damaged or inadequate integumental tissue. They help provide mechanical support and allow for cellular repopulation. Acellular dermal matrices are commonly used in breast reconstructive surgeries following mastectomy to form pockets for breast implants. They are also utilized in hernia repair surgeries and other procedures that require tissue reinforcement or replacement. The global acellular dermal matrices market has seen steady growth in recent years driven by the rising incidence of breast cancer prompting a higher number of mastectomies and breast reconstruction procedures. The aging global population susceptible to hernias has also created demand for acellular dermal matrices to repair hernias. The global Acellular Dermal Matrices Market is estimated to be valued at US$ 8.8 Bn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

Research efforts are ongoing to improve the properties of acellular dermal matrices. Scientists are exploring new techniques to decellularize dermal tissue with the goal of better mimicking native dermal properties like mechanical strength and cellular repopulation. There is also development of acellular matrices that incorporate growth factors and bioactive molecules to enhance tissue regeneration and wound healing characteristics. With advancements, newer generation acellular dermal matrices are expected to demonstrate better clinical outcomes making them preferred options among surgeons. Greater awareness about breast reconstruction options is also expected to continue driving the demand for acellular dermal matrices used in breast reconstruction procedures.

Porter’s Analysis

Threat of new entrants: The acellular dermal matrices market requires considerable investments in R&D to develop new products, which poses a barrier for new companies to enter the market.

Bargaining power of buyers: The bargaining power of buyers is moderate as acellular dermal matrices have few substitutes and customers have to rely on a few major companies.

Bargaining power of suppliers: Suppliers have moderate bargaining power due to the specialized nature of inputs required for manufacturing acellular dermal matrices.

Threat of new substitutes: There exist few substitutes for acellular dermal matrices, reducing the threat from new substitutes.

Competitive rivalry: The acellular dermal matrices market is consolidated with large players dominating the market. Competition is high based on product quality, innovation, and pricing.

Key Takeaways

The Global Acellular Dermal Matrices Market Size is expected to witness high growth over the forecast period. North America is expected to dominate the market during the forecast period owing to high healthcare spending and growing number of cosmetic surgeries in the region. Key players in the acellular dermal matrices market include Regenacy Pharmaceuticals, Inc., Astex Pharmaceuticals, 4SC AG, CellCentric Ltd., Celleron Therapeutics Ltd., Bristol-Myers Squibb Company, Oryzon Genomics S.A., ChromaMedicine, Inc., Epizyme, Inc., and EpiGentek Group Inc.

The acellular dermal matrices market in North America is expected to grow at a high rate due to rapid increase in cosmetic surgeries and trauma cases in the region. Availability of advanced healthcare facilities and high healthcare expenditure also augment the market growth.

Key players operating in the acellular dermal matrices market are Regenacy Pharmaceuticals, Inc., Astex Pharmaceuticals, 4SC AG, CellCentric Ltd., Celleron Therapeutics Ltd., Bristol-Myers Squibb Company, Oryzon Genomics S.A., ChromaMedicine, Inc., Epizyme, Inc., and EpiGentek Group Inc. These players are focusing on new product launches and geographical expansions to strengthen their market position.

*Note:
1.      Source: Coherent Market Insights, Public sources, Desk research
2.      We have leveraged AI tools to mine information and compile it